Abstract
In four patients with hemophilia, or von Willebrand's disease, intensive infusion therapy with lyophilized plasma, cryoprecipitate, (Courtland Laboratories), a commercial preparation of fibrinogen and antihemophilic globulin (Fibro-AHF), or antihemophilic globulin (Hemofil) produced hemolysis. The recipients were of blood group A or AB. These materials contained the naturally occurring isoantibodies to A and B erythrocyte antigens. Hemolysis was noted only with intensive replacement therapy. Type-specific cryoprecipitate should be given when prolonged infusion therapy is required following surgical procedures.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
